Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

University of Maryland, Baltimore · 2021
ClinicalTrials.gov · Datasets · License: Public Domain · 2021
Open Source ↗
relapsed or refractory acute myeloid leukemia, pegcrisantaspase, venetoclax, relapsed or refractory acute myeloid leukemia (r/r aml), ven-pegc, maximum tolerated doses, recommended phase 2 doses, incidence of regimen limiting toxicities, incidence of treatment-emergent adverse events, interventional, phase1
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 849659
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.